ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$47.9M 137,083 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. reported $48,075,723.50 across General Payments, Research, and Ownership to 94,811 physicians and teaching hospitals across 106,116 transactions.
- $48.1M
- All-tracks total
- 106,116
- Transactions
- 94,811
- Recipients
- −$1.7M
- General Payments vs PY2023
Sumitomo Pharma America, Inc. reported $48,075,723.50 across all CMS Open Payments tracks (General + Research + Ownership) to 94,811 physicians and teaching hospitals in Program Year 2024 - ranking #49 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $3,805,644.96, averaging $507.07 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sumitomo-pharma-america-inc Sumitomo Pharma America, Inc.
$48.1M · #49/1,925 · 0.3% industry · PY2024
- TOT $48.1M
- RANK #49
- SHARE 0.3%
- TXN 106,116
- RCP 94,811
- CAT 6
- GEN $3.8M
- ΔGEN −$1.7M
- TOP1 3.2%
- PY 2024
Volume peers
Nearest volume peer: ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($47.9M)
Sumitomo Pharma America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sumitomo Pharma America, Inc.'s CMS-reported General Payments decreased by $1.7M (−30.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: SUMITOMO PHARMA AMERICA, INC.PY2024: Sumitomo Pharma America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $5,478,809.67
- PY2024
- $3,805,644.96
What the Data Shows for Sumitomo Pharma America, Inc.
Averaging $453.05 per transaction and $507.07 per recipient, Sumitomo Pharma America, Inc.'s Program Year 2024 total comes to $48,075,723.50 across 106,116 transactions and 94,811 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #49 of 1,925 companies, representing 0.3% of all industry payments reported nationwide for the year.
"Food and Beverage" leads the 6-category general-payment breakdown below at $1.9M (49.1% of General Payments, 93,174 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Sumitomo Pharma America, Inc. made 6 types of general payments. "Food and Beverage" is the largest category at $1.9M, 49.1% of General Payments.
Sumitomo Pharma America, Inc. reports 6 general-payment categories - the top three are Food and Beverage (49.1%), Consulting Fee (23.5%), and Compensation for Services Other Than Consulting (19.7%). The remaining 3 categories make up 7.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Sumitomo Pharma America, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.9M | 93,174 | 49.1% |
| Consulting Fee | $892.8K | 275 | 23.5% |
| Compensation for Services Other Than Consulting | $750.5K | 1,031 | 19.7% |
| Grant | $216.0K | 43 | 5.7% |
| Travel and Lodging | $75.3K | 173 | 2.0% |
| Education | $2.4K | 115 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $417,497.85 (11.0%) of $3,805,644.96 in this company's General Payments records across 31,102 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sumitomo Pharma America, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
William White
$119,915.00 across 11 reported transactions
- 2
The Childrens Hospital of Philadelp
$99,360.00 across 11 reported transactions
- 3
Matt Rosenberg
$75,097.66 across 67 reported transactions
- 4
David Staskin
$65,628.72 across 43 reported transactions
- 5
Aviva Asnis-Alibozek
$57,496.47 across 11 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sumitomo Pharma America, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sumitomo Pharma America, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sumitomo Pharma America, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Cleerly, Inc.
$47.5M 910 recipients
Compare payment profiles
Scientia Vascular
$46.9M 191 recipients
Compare payment profiles
Novo Nordisk AS
$49.2M 804 recipients
Compare payment profiles
Vektor Medical Inc.
$49.6M 56 recipients
Compare payment profiles
Smith+Nephew, Inc.
$50.5M 71,450 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.